Panagiotis Pavlou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Panagiotis Pavlou has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Janaka Karalliedde
School of Cardiovascular and Metabolic Medicine and Sciences King's College London London UK
6 shared publications Salma Ayis
School of Life Course and Population Sciences, King’s College London
4 shared publicationsAnna Brackenridge
Department of Diabetes and Endocrinology Guy's and St Thomas' NHS Foundation Trust London UK
3 shared publicationsStephen Thomas
Guy’s and St Thomas’ NHS Foundation Trust
3 shared publicationsThomas Johnston
Guy’s and St Thomas’ NHS Foundation Trust
3 shared publicationsDulmini Kariyawasam
Guy’s and St Thomas’ NHS Foundation Trust
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1908356
The effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study
Introduction: In animal models of diabetic kidney disease (DKD), ursodeoxycholic acid (UDCA) reduces albuminuria and improves histological changes associated with DKD. The purpose of this study was to investigate the potential renoprotective role of UDCA in people with type 1 diabetes (T1D) and DKD. Methods: In this single-centre, double-blind, placebo-controlled crossover trial, participants with T1D and DKD with residual albuminuria (urine albumin to creatinine ratio, > 3 mg/mmol) on a maximum tolerated, stable dose of renin–angiotensin system (RAS) blockade with estimated glomerular filtration rate (eGFR) ≥ 30 ml/min were included. Participants were randomly allocated to UDCA (500 mg BID) or placebo for 24 weeks, with a 4-week washout period in between. The primary endpoint was the change in urine albumin excretion rate (UAER), measured from timed urine collections after 24 weeks of treatment with UDCA compared with placebo. Results: Thirty-one participants were included, of whom 21 were men; the median age (interquartile range [IQR]) was 54.2 (22.7–75.3) years. The baseline median (IQR) UAER was 26 (12.3–189.0) μg/min for UDCA and 32.1 (19.9–88.2) μg/min for placebo. The median (IQR) posttreatment UAER was 36.2 (14.9–174.0) μg/min for UDCA and 38.5 (17.6–194.0) μg/min for placebo, with no significant difference in UAER between treatments ( p -value = 0.4). Conclusion: In this first-ever human study investigating the potential renoprotective effect of UDCA treatment for 24 weeks in people with T1D and DKD, we did not observe a significant reduction in UAER. Further studies are required to evaluate the role of UDCA in DKD. Clinical trial registration: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003609-41 , identifier 2015-003609-41.
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1908356
Open AccessThe effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study
Introduction: In animal models of diabetic kidney disease (DKD), ursodeoxycholic acid (UDCA) reduces albuminuria and improves histological changes associated with DKD. The purpose of this study was to investigate the potential renoprotective role of UDCA in people with type 1 diabetes (T1D) and DKD. Methods: In this single-centre, double-blind, placebo-controlled crossover trial, participants with T1D and DKD with residual albuminuria (urine albumin to creatinine ratio, > 3 mg/mmol) on a maximum tolerated, stable dose of renin–angiotensin system (RAS) blockade with estimated glomerular filtration rate (eGFR) ≥ 30 ml/min were included. Participants were randomly allocated to UDCA (500 mg BID) or placebo for 24 weeks, with a 4-week washout period in between. The primary endpoint was the change in urine albumin excretion rate (UAER), measured from timed urine collections after 24 weeks of treatment with UDCA compared with placebo. Results: Thirty-one participants were included, of whom 21 were men; the median age (interquartile range [IQR]) was 54.2 (22.7–75.3) years. The baseline median (IQR) UAER was 26 (12.3–189.0) μg/min for UDCA and 32.1 (19.9–88.2) μg/min for placebo. The median (IQR) posttreatment UAER was 36.2 (14.9–174.0) μg/min for UDCA and 38.5 (17.6–194.0) μg/min for placebo, with no significant difference in UAER between treatments ( p -value = 0.4). Conclusion: In this first-ever human study investigating the potential renoprotective effect of UDCA treatment for 24 weeks in people with T1D and DKD, we did not observe a significant reduction in UAER. Further studies are required to evaluate the role of UDCA in DKD. Clinical trial registration: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003609-41 , identifier 2015-003609-41.
- 28 July 2026
- Published by Wiley in Diabetic Medicine
- p. e70439
Immune checkpoint inhibitor‐induced diabetes mellitus: A case series from a large tertiary centre in the UK
Aims: Immune checkpoint inhibitors (ICI) have transformed oncology treatment. This study presents a case series of adults diagnosed with ICI‐induced diabetes mellitus (ICI‐DM) and evaluates the challenges involved in the diagnosis and management of this rare immunotherapy side‐effect. Methods: A single‐centre case series from the UK involved individuals who developed new onset insulin dependent diabetes after ICI treatment between 2017 and 2026. Data were extracted from the electronic medical records (EPIC® Systems Corporation). Results: Thirteen individuals (61.5% male, median age: 61 years [IQR 45–71]) diagnosed with ICI‐DM were included. The majority were from a White ethnic background (84.6%). Time from ICI start to ICI‐DM presentation had a median of 4 months (IQR 2–18). Most ( n = 9, 69.2%) presented with diabetic ketoacidosis (DKA), with two requiring intensive care. Importantly three cases of DKA were potentially avoidable with earlier insulin initiation. Diabetes autoantibodies were positive in 54.5% (5 with GAD65 and 1 with IA‐2 antibodies) with median C‐peptide levels at diagnosis 161 pmol/L (IQR 10–232). The mean HbA1c before ICI start was 40 7 mmol/mol (5.8 ± 2.8%) climbing to 80 ± 15 mmol/mol (9.5 ± 3.5%) at diagnosis, within a median interval of 3 months (IQR 2–4). Conclusions: It is essential to increase healthcare professional awareness of immunotherapy side‐effects to achieve early recognition and prompt management. Increased use of capillary glucose testing and immunotherapy alert card can improve outcomes. Future studies can investigate the relationship between potential risk factors and predisposition to ICI‐DM development.
- 28 July 2026
- Published by Wiley in Diabetic Medicine
- p. e70439
Immune checkpoint inhibitor‐induced diabetes mellitus: A case series from a large tertiary centre in the UK
Aims: Immune checkpoint inhibitors (ICI) have transformed oncology treatment. This study presents a case series of adults diagnosed with ICI‐induced diabetes mellitus (ICI‐DM) and evaluates the challenges involved in the diagnosis and management of this rare immunotherapy side‐effect. Methods: A single‐centre case series from the UK involved individuals who developed new onset insulin dependent diabetes after ICI treatment between 2017 and 2026. Data were extracted from the electronic medical records (EPIC® Systems Corporation). Results: Thirteen individuals (61.5% male, median age: 61 years [IQR 45–71]) diagnosed with ICI‐DM were included. The majority were from a White ethnic background (84.6%). Time from ICI start to ICI‐DM presentation had a median of 4 months (IQR 2–18). Most ( n = 9, 69.2%) presented with diabetic ketoacidosis (DKA), with two requiring intensive care. Importantly three cases of DKA were potentially avoidable with earlier insulin initiation. Diabetes autoantibodies were positive in 54.5% (5 with GAD65 and 1 with IA‐2 antibodies) with median C‐peptide levels at diagnosis 161 pmol/L (IQR 10–232). The mean HbA1c before ICI start was 40 7 mmol/mol (5.8 ± 2.8%) climbing to 80 ± 15 mmol/mol (9.5 ± 3.5%) at diagnosis, within a median interval of 3 months (IQR 2–4). Conclusions: It is essential to increase healthcare professional awareness of immunotherapy side‐effects to achieve early recognition and prompt management. Increased use of capillary glucose testing and immunotherapy alert card can improve outcomes. Future studies can investigate the relationship between potential risk factors and predisposition to ICI‐DM development.
- Open Access
- 29 April 2026
- Published by SAGE Publications in Health Informatics Journal
- Vol. 32 (2)
An informatics-based data-led prioritization strategy to facilitate objective and equitable care for an ethnically diverse urban cohort of people with type 1 diabetes: A proof-of-concept study
Background: Ethnicity and socioeconomic factors contribute to higher morbidity and mortality in people with type 1 diabetes (pwT1D), partly due to reduced access to specialised care and technology. Objectively prioritising high-risk individuals in resource-limited settings is challenging. Data-led prioritisation (DLP) uses health informatics to stratify pwT1D based on new-onset risk factors since their last review. This may help overcome implicit bias, structural racism, and care barriers. However, data on its use in pwT1D are limited. Methods: In this proof-of-concept study, DLP was implemented from July to September 2023 in a university hospital serving an ethnically diverse population. Clinical and demographic data were collected from 697 adults with T1D (50.5% female, 23.5% non-White, 37% from poor socioeconomic backgrounds). DLP identified 76 individuals (10.9%) as highest risk. Results: Non-White patients were more likely to be in the highest-risk group (30/164, 18.3%) than White patients (35/372, 9.4%), p =0.004. Those from the most deprived socioeconomic backgrounds were also more likely to be high-risk (40/256, 15.7%) vs others (36/433, 8.3%), p =0.008. Conclusion: DLP may enable objective risk stratification in pwT1D and could help reduce bias linked to ethnicity and deprivation. Further large-scale research is warranted to demonstrate the use of such systems in diabetes care.
- 29 April 2026
- Published by SAGE Publications in Health Informatics Journal
- Vol. 32 (2)
Open AccessAn informatics-based data-led prioritization strategy to facilitate objective and equitable care for an ethnically diverse urban cohort of people with type 1 diabetes: A proof-of-concept study
Background: Ethnicity and socioeconomic factors contribute to higher morbidity and mortality in people with type 1 diabetes (pwT1D), partly due to reduced access to specialised care and technology. Objectively prioritising high-risk individuals in resource-limited settings is challenging. Data-led prioritisation (DLP) uses health informatics to stratify pwT1D based on new-onset risk factors since their last review. This may help overcome implicit bias, structural racism, and care barriers. However, data on its use in pwT1D are limited. Methods: In this proof-of-concept study, DLP was implemented from July to September 2023 in a university hospital serving an ethnically diverse population. Clinical and demographic data were collected from 697 adults with T1D (50.5% female, 23.5% non-White, 37% from poor socioeconomic backgrounds). DLP identified 76 individuals (10.9%) as highest risk. Results: Non-White patients were more likely to be in the highest-risk group (30/164, 18.3%) than White patients (35/372, 9.4%), p =0.004. Those from the most deprived socioeconomic backgrounds were also more likely to be high-risk (40/256, 15.7%) vs others (36/433, 8.3%), p =0.008. Conclusion: DLP may enable objective risk stratification in pwT1D and could help reduce bias linked to ethnicity and deprivation. Further large-scale research is warranted to demonstrate the use of such systems in diabetes care.
- Open Access
- 1 April 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (7) , 2061-2072
The impact of blood pressure variability and African Caribbean ethnicity on the progression of diabetic kidney disease in type 1 diabetes
Aims/hypothesis: Blood pressure variability (BPV) is a risk factor for kidney disease progression in hypertension and type 2 diabetes; however, the role of BPV in kidney disease in type 1 diabetes is unknown. The aim of this study was therefore to determine whether BPV has an impact on kidney disease progression in an ethnically diverse cohort of people with type 1 diabetes. Methods: We studied 3079 people (median age 36 [range 18–85] years; 50% female; 78.5% White, 10.9% African Caribbean, 4.5% Asian, 6.1% Other) with type 1 diabetes and baseline eGFR >45 ml/min per 1.73m 2 attending two university hospital clinics between 2004 and 2018. BPV was assessed using visit-adjusted standard deviation (adj-SD), CV and average real variability (ARV) for systolic blood pressure (SBP) and diastolic blood pressure (DBP). The primary endpoint was eGFR decline of ≥50% from baseline with final eGFR 2 , with death as a competing risk. Results: Over a 14 year period, 272 people (8.8%) reached the primary endpoint. All BPV metrics for SBP and DBP were significantly associated with the primary endpoint. ARVs of SBP and DBP and African Caribbean ethnicity emerged as risk factors in multivariable analyses, independent of traditional risk factors, including baseline blood pressure, eGFR, HbA 1c , albuminuria and mean blood pressure in the exposure window. The strongest association was observed for the ARV of SBP (HR 1.54, 95% CI 1.27, 1.87, p <0.001). Conclusions/interpretation: In people with type 1 diabetes, SBP and DBP variability are associated with kidney disease progression. Further studies are needed to investigate if BPV is a modifiable risk factor for kidney disease progression.
- 1 April 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (7) , 2061-2072
Open AccessThe impact of blood pressure variability and African Caribbean ethnicity on the progression of diabetic kidney disease in type 1 diabetes
Aims/hypothesis: Blood pressure variability (BPV) is a risk factor for kidney disease progression in hypertension and type 2 diabetes; however, the role of BPV in kidney disease in type 1 diabetes is unknown. The aim of this study was therefore to determine whether BPV has an impact on kidney disease progression in an ethnically diverse cohort of people with type 1 diabetes. Methods: We studied 3079 people (median age 36 [range 18–85] years; 50% female; 78.5% White, 10.9% African Caribbean, 4.5% Asian, 6.1% Other) with type 1 diabetes and baseline eGFR >45 ml/min per 1.73m 2 attending two university hospital clinics between 2004 and 2018. BPV was assessed using visit-adjusted standard deviation (adj-SD), CV and average real variability (ARV) for systolic blood pressure (SBP) and diastolic blood pressure (DBP). The primary endpoint was eGFR decline of ≥50% from baseline with final eGFR 2 , with death as a competing risk. Results: Over a 14 year period, 272 people (8.8%) reached the primary endpoint. All BPV metrics for SBP and DBP were significantly associated with the primary endpoint. ARVs of SBP and DBP and African Caribbean ethnicity emerged as risk factors in multivariable analyses, independent of traditional risk factors, including baseline blood pressure, eGFR, HbA 1c , albuminuria and mean blood pressure in the exposure window. The strongest association was observed for the ARV of SBP (HR 1.54, 95% CI 1.27, 1.87, p <0.001). Conclusions/interpretation: In people with type 1 diabetes, SBP and DBP variability are associated with kidney disease progression. Further studies are needed to investigate if BPV is a modifiable risk factor for kidney disease progression.
- Open Access
- 19 March 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (3) , e70148
Impact of Body Mass Index Variability on Kidney Disease Progression in a Large Type 1 Diabetes Cohort
Aims: Body mass index (BMI) variability an index of ‘metabolic cycling’ predicts kidney disease in type 2 diabetes, but studies in people with type 1 diabetes (pwT1DM) are scarce. We examined the relationship between BMI variability and diabetic kidney disease (DKD) progression in an ethnically diverse cohort of pwT1DM. Methods: We analysed 3270 pwT1DM (52% female, 80% white) with baseline eGFR ≥ 45 mL/min/1.73 m 2 and ≥ 6 BMI measurements, attending two university hospital clinics (between 2004 and 2018). BMI variability was assessed using standard deviation (SD), visit‐adjusted SD, variability independent of the mean (VIM), and average real variability (ARV). The primary endpoint was ≥ 50% eGFR decline with final eGFR < 30 mL/min/1.73 m 2 . Multivariable and competing risk analyses (with mortality as competing risk) were performed. Results: Over a median of 9.6 years, 179 (5.5%) people reached the primary endpoint. Those who reached the primary endpoint had higher BMI variability, with baseline higher age, HbA1c, systolic blood pressure, albuminuria levels, and were more often of African‐Carribean ethnicity as compared to those who did not. In multivariable models and competing risk analyses, all BMI variability indices were independent risk‐factors for the primary endpoint. Visit‐adjusted SD (HR 2.43, 95% CI 1.93–3.05) and ARV (HR 1.7, 95% CI 1.44–2.01) were the strongest BMI variability indices associated with the primary endpoint. Conclusion: BMI variability is an independent predictor of DKD progression in pwT1DM. Further studies are required to elucidate the underlying mechanisms of our observations and explore if addressing BMI variability can translate to clinical benefits in DKD.
- 19 March 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (3) , e70148
Open AccessImpact of Body Mass Index Variability on Kidney Disease Progression in a Large Type 1 Diabetes Cohort
Aims: Body mass index (BMI) variability an index of ‘metabolic cycling’ predicts kidney disease in type 2 diabetes, but studies in people with type 1 diabetes (pwT1DM) are scarce. We examined the relationship between BMI variability and diabetic kidney disease (DKD) progression in an ethnically diverse cohort of pwT1DM. Methods: We analysed 3270 pwT1DM (52% female, 80% white) with baseline eGFR ≥ 45 mL/min/1.73 m 2 and ≥ 6 BMI measurements, attending two university hospital clinics (between 2004 and 2018). BMI variability was assessed using standard deviation (SD), visit‐adjusted SD, variability independent of the mean (VIM), and average real variability (ARV). The primary endpoint was ≥ 50% eGFR decline with final eGFR < 30 mL/min/1.73 m 2 . Multivariable and competing risk analyses (with mortality as competing risk) were performed. Results: Over a median of 9.6 years, 179 (5.5%) people reached the primary endpoint. Those who reached the primary endpoint had higher BMI variability, with baseline higher age, HbA1c, systolic blood pressure, albuminuria levels, and were more often of African‐Carribean ethnicity as compared to those who did not. In multivariable models and competing risk analyses, all BMI variability indices were independent risk‐factors for the primary endpoint. Visit‐adjusted SD (HR 2.43, 95% CI 1.93–3.05) and ARV (HR 1.7, 95% CI 1.44–2.01) were the strongest BMI variability indices associated with the primary endpoint. Conclusion: BMI variability is an independent predictor of DKD progression in pwT1DM. Further studies are required to elucidate the underlying mechanisms of our observations and explore if addressing BMI variability can translate to clinical benefits in DKD.
- Open Access
- 18 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 2953-2961
Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial
Objective: People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao‐PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide‐1 receptor agonist (GLP‐1 RA) class demonstrate notable differences, with lixisenatide having neutral effects as compared to longer acting GLP‐1 RA. It is unknown if shorter acting GLP‐1 RA have an impact on Ao‐PWV and if this may explain the discordance observed in GLP‐1RA CVOTs. Materials and Methods: We studied people with type 2 diabetes and CKD in a proof‐of‐concept single centre, randomised, double‐blind parallel‐group placebo‐controlled study that evaluated 24 weeks' treatment with lixisenatide as compared to placebo on the primary endpoint of Ao‐PWV. Results: In total, 101 participants (male 66%) were randomised of whom 90 were eligible for analyses (lixisenatide [ n = 47] and placebo [ n = 43]). Ao‐PWV did not change significantly from baseline after 24 weeks of treatment with final mean (95% confidence intervals) of 9.65 (9.17, 10.13) m/s with lixisenatide and 9.96 (9.45, 10.46) m/s with placebo, p = 0.38. Similarly, no significant changes were observed in cardio‐renal risk biomarkers including albuminuria and Klotho levels. HbA1c decreased with lixisenatide as compared to placebo. Conclusions: In people with CKD and type 2 diabetes the use of short‐acting GLP‐1 RA lixisenatide did not significantly influence Ao‐PWV. Further studies are needed to understand mechanisms that may explain discordance in CVOTs results observed with GLP‐1 RA. Clinical Trial Registration: ISRCTN: ISRCTN97699312; EudraCT/CTIS number: 2016‐001758‐17.
- 18 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 2953-2961
Open AccessEffect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial
Objective: People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao‐PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide‐1 receptor agonist (GLP‐1 RA) class demonstrate notable differences, with lixisenatide having neutral effects as compared to longer acting GLP‐1 RA. It is unknown if shorter acting GLP‐1 RA have an impact on Ao‐PWV and if this may explain the discordance observed in GLP‐1RA CVOTs. Materials and Methods: We studied people with type 2 diabetes and CKD in a proof‐of‐concept single centre, randomised, double‐blind parallel‐group placebo‐controlled study that evaluated 24 weeks' treatment with lixisenatide as compared to placebo on the primary endpoint of Ao‐PWV. Results: In total, 101 participants (male 66%) were randomised of whom 90 were eligible for analyses (lixisenatide [ n = 47] and placebo [ n = 43]). Ao‐PWV did not change significantly from baseline after 24 weeks of treatment with final mean (95% confidence intervals) of 9.65 (9.17, 10.13) m/s with lixisenatide and 9.96 (9.45, 10.46) m/s with placebo, p = 0.38. Similarly, no significant changes were observed in cardio‐renal risk biomarkers including albuminuria and Klotho levels. HbA1c decreased with lixisenatide as compared to placebo. Conclusions: In people with CKD and type 2 diabetes the use of short‐acting GLP‐1 RA lixisenatide did not significantly influence Ao‐PWV. Further studies are needed to understand mechanisms that may explain discordance in CVOTs results observed with GLP‐1 RA. Clinical Trial Registration: ISRCTN: ISRCTN97699312; EudraCT/CTIS number: 2016‐001758‐17.
- Open Access
- 26 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3424-3428
Discordant real‐world glycaemic outcomes with Omnipod™ 5 and MiniMed™ 780G in adults with type 1 diabetes: Why validated measures matter
- 26 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3424-3428
Open AccessDiscordant real‐world glycaemic outcomes with Omnipod™ 5 and MiniMed™ 780G in adults with type 1 diabetes: Why validated measures matter
- Open Access
- 26 January 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (2)
Exocrine Pancreatic Insufficiency Manifesting Before Insulin Dependence in Adult‐Onset Type 1 Diabetes
Exocrine pancreatic insufficiency may precede insulin dependence in adult‐onset type 1 diabetes. Unexplained steatorrhea or weight loss in people with diabetes warrants further investigations including imaging of abdomen/pancreas, exocrine pancreatic function and diabetes antibody testing. Early recognition and multidisciplinary care lead to improvements in symptoms and glycemic control.
- 26 January 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (2)
Open AccessExocrine Pancreatic Insufficiency Manifesting Before Insulin Dependence in Adult‐Onset Type 1 Diabetes
Exocrine pancreatic insufficiency may precede insulin dependence in adult‐onset type 1 diabetes. Unexplained steatorrhea or weight loss in people with diabetes warrants further investigations including imaging of abdomen/pancreas, exocrine pancreatic function and diabetes antibody testing. Early recognition and multidisciplinary care lead to improvements in symptoms and glycemic control.
- Open Access
- 19 August 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (11) , 2027-2032
Using automated insulin delivery to address the clinical challenges of glycemic management in people with type 1 diabetes and kidney failure on maintenance hemodialysis
Diabetes management in end‐stage kidney disease (ESKD) is complicated by altered insulin pharmacokinetics and glucose metabolism, particularly in the context of hemodialysis (HD). Automated insulin delivery (AID) systems offer dynamic insulin adjustment and may help address these challenges. We present real‐world data from nine individuals (five females) with type 1 diabetes and ESKD on HD, median age 38 years (range 33–50). Over a median follow‐up of 7 months (range 1.5–25), AID use led to significant improvements in glucose time in range (3.9–10 mmol/l) which increased from 39.7% to 59.8% ( P = 0.001), glucose variability decreased from 39.8% to 33.8% ( P = 0.01), and HbA1c improved from 78.6 to 56.1 mmol/mol ( P = 0.003). Time below range fell from 4.0% to 1.4%, but this was not significant ( P = 0.1). AID was well tolerated and implemented with multidisciplinary support. Our findings highlight the potential of AID to improve glycemic control in this high‐risk population and the need for further studies in this area.
- 19 August 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (11) , 2027-2032
Open AccessUsing automated insulin delivery to address the clinical challenges of glycemic management in people with type 1 diabetes and kidney failure on maintenance hemodialysis
Diabetes management in end‐stage kidney disease (ESKD) is complicated by altered insulin pharmacokinetics and glucose metabolism, particularly in the context of hemodialysis (HD). Automated insulin delivery (AID) systems offer dynamic insulin adjustment and may help address these challenges. We present real‐world data from nine individuals (five females) with type 1 diabetes and ESKD on HD, median age 38 years (range 33–50). Over a median follow‐up of 7 months (range 1.5–25), AID use led to significant improvements in glucose time in range (3.9–10 mmol/l) which increased from 39.7% to 59.8% ( P = 0.001), glucose variability decreased from 39.8% to 33.8% ( P = 0.01), and HbA1c improved from 78.6 to 56.1 mmol/mol ( P = 0.003). Time below range fell from 4.0% to 1.4%, but this was not significant ( P = 0.1). AID was well tolerated and implemented with multidisciplinary support. Our findings highlight the potential of AID to improve glycemic control in this high‐risk population and the need for further studies in this area.